“We’ve got to make sure those who need [Repatha] can get it,” says Robert Bradway, Amgen’s chairman and chief executive. “The losers are the patients who have gone to the pharmacy counter and have not been able to get the medicine they need.”
In Unprecedented Move, Amgen Cuts Price Of Cholesterol Drug Repatha By 60%
